NewsDesk @bactiman63 Enrollment in a Phase 1 trial of a new investigational universal influenza vaccine candidate has begun at the National Institutes of Health’s Clinical Center in Bethesda, Maryland....

A vaccine that induces immune responses to a wide spectrum of influenza virus strains and subtypes has produced strong and durable results in early-stage clinical trials in humans, Mount Sinai researchers...

Each year, the flu vaccine has to be redesigned to account for mutations that the virus accumulates, and even then, the vaccine is often not fully protective for everyone. Researchers at MIT and the Ragon...

An experimental vaccine designed to protect against many flu virus strains has yielded promising results in an efficacy trial. NIAID investigator Matthew J. Memoli, M.D., designed and led the trial, which...

A novel nanoparticle vaccine that combines two major influenza proteins is effective in providing broad, long-lasting protection against influenza virus in mice, showing promise as a universal flu vaccine,...

By Robert Herriman  @bactiman63 As 2019 comes to a close, the number of big, important infectious disease news and outbreak was in no shortage since January. So, it becomes my annual task to try to...

Osivax announced Thursday that it has entered into an agreement with the United States’ National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH),...

Vaccitech Ltd. announced that it has administered its pandemic universal influenza A vaccine MVA-NP+M1 (VTP-100) to the first participants in a Flu 010 study – a Phase 2b, randomised, double-blind, placebo...

My first guest on the new YouTube program, Outbreak News TV is public health scientist, infectious disease expert and director of the Center for Infectious Disease Research and Policy, or CIDRAP at the...

My first guest on the new YouTube program, Outbreak News TV is public health scientist, infectious disease expert and director of the Center for Infectious Disease Research and Policy, or CIDRAP at the...